Drug Profile


Alternative Names: Erlosiban; OBE-001; Oxytocin antagonist - ObsEva

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck Serono
  • Developer ObsEva
  • Class Oximes; Pyrrolidinones; Small molecules; Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Female infertility
  • Phase II Preterm labour

Most Recent Events

  • 29 Jun 2017 Efficacy data from the phase II IMPLANT trial for Female infertility released by ObsEva
  • 22 Feb 2017 Phase-III clinical trials in Female infertility in Belgium (PO) (EudraCT2016-004266-25)
  • 17 Jan 2017 ObsEva terminates a phase II trial in Preterm labour in Belgium, Germany, Poland, Spain, Switzerland and the UK(NCT02326142)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top